BTIG analyst Julian Harrison has maintained their neutral stance on UTHR stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Julian Harrison’s rating is based on the promising results from the TETON-2 trial, which demonstrated significant improvement in lung function for patients using inhaled treprostinil. The trial’s success highlights the potential of this treatment for IPF patients, showing benefits across various subgroups. However, despite these positive outcomes, there are still key near-term risks that warrant a cautious approach.
The competition from other treatments like Yutrepia and uncertainties surrounding the potential label expansion for Tyvaso contribute to the Hold rating. Additionally, while the TETON-2 results are encouraging, the final outcomes of the TETON-1 trial and the overall market dynamics will play a crucial role in the future performance of United Therapeutics. Therefore, while the long-term prospects appear promising, the current uncertainties justify a neutral stance.
In another report released yesterday, Bank of America Securities also reiterated a Hold rating on the stock with a $463.00 price target.
Based on the recent corporate insider activity of 143 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year.